Kairos Pharma to acquire CL-273 from Celyn Therapeutics for $16.2 bln market opportunity.

Kairos Pharma has signed binding terms to acquire CL-273, a pan-EGFR inhibitor for EGFR-mutant lung cancer, from Celyn Therapeutics. The deal expands Kairos Pharma's oncology pipeline and targets a $16.2 billion market opportunity. The acquisition of CL-273 follows the company's recent collaboration with Entos Pharmaceuticals to develop a novel, AI-designed cancer vaccine.